Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 for Long-Term Post-GLP-1 Weight Management
Response Pharmaceuticals Reports Positive 36-Week Phase 2 Data Supporting RDX-002 as a Long-Term Option in Post-GLP-1 Receptor Agonist Weight Management Response Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for…
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for Brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus Mirum Pharmaceuticals, Inc. a leading rare disease company, today announced completion of enrollment in the Phase…
DiaMedica Therapeutics Receives Health Canada Clearance to Launch Phase 2 Study of DM199 for Preeclampsia
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal…
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full-Year 2025 Financial Results
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results Silence Therapeutics plc, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies,…
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs
Liberate Bio Secures Myeloid-Optimized CAR Design Licenses to Advance In Vivo CAR-M Programs Liberate Bio, Inc., a biotechnology company developing genetic medicines that deliver RNA therapies directly to immune cells,…
Parabilis Medicines Reports Early Clinical Evidence Showing Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis
Parabilis Medicines Reports Early Clinical Evidence that Zolucatetide Reduces Polyp Burden in a Patient with Familial Adenomatous Polyposis Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for…
Verastem Oncology Reports 2025 Financial Results and Updates
Verastem Oncology Reports Strong Progress in 2025 with Drug Launch, Pipeline Advances, and Financial Updates Verastem Oncology reported its financial results for the fourth quarter and full year ending December 31, 2025,…
Xencor Updates Forecast for Ultomiris® Royalty Revenue
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals,…
ImmunoScape Signs MOU for Clinical Trial with Leading U.S. Cancer Center
ImmunoScape Announces Memorandum of Understanding for Clinical Trial with Premier U.S. Cancer Center ImmunoScape Pte. Ltd., an A*STAR spin-out backed by Amgen Ventures and EDBI that is developing next-generation TCR-based…
Vasomune Therapeutics, Inc. and AnGes, Inc. Secure FDA IND Clearance
Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients Vasomune Therapeutics, Inc., a…
Affinia Therapeutics’ AFTX-201 Earns FDA Fast Track Designation for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline…
Real Chemistry Reports Robust 2025 Performance with Continued Double-Digit Expansion
Real Chemistry Delivers Double-Digit Year-Over-Year Growth in 2025 as Tier-One, Tech-Enabled Healthcare Commercialization Partner Real Chemistry today announced results for the fiscal year ending December 31, 2025, underscoring sustained momentum…